Clinical AI Leader Navina Secures $55M Series C Funding Led by Growth Equity at Goldman Sachs Alternatives
Summary
Investment will fuel the advancement of its AI-powered clinical intelligence platform, transforming patient care and value-based care outcomesNEW YORK, March 25, 2025 /PRNewswire/ -- Navina, a market leader in AI-powered clinical intelligence, today announced the successful completion of a $55 million Series C funding round, bringing the total funding to $100 million. The round is led by Growth Equity at Goldman Sachs Alternatives, with participation from existing investors, including Vertex Ventures Israel, Grove Ventures and ALIVE.This significant investment will accelerate Navinas expansion across the U.S. healthcare market, enhance its proprietary AI technology, and further drive improvements in patient outcomes by bringing proactive clinical intelligence to every outpatient interaction. "Their deep integration into clinical workflows, unparalleled provider trust, and demonstrated ROI make them uniquely positioned to drive meaningful impact across the healthcare ecosystem. Navinas AI copilot surfaces clinical insights that support effective decision-making throughout the care continuumfrom the back office to the point of carewhile significantly reducing the administrative burden. Designed for and loved by physicians, Navina reduces missed diagnoses, improves quality metrics and risk adjustment accuracy, and alleviates the administrative burdenallowing providers to focus on what matters most: their patients.